Media headlines about Apellis Pharmaceuticals (NASDAQ:APLS) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Apellis Pharmaceuticals earned a news impact score of 0.07 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.0687063353007 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

A number of equities analysts have commented on the stock. Evercore ISI assumed coverage on shares of Apellis Pharmaceuticals in a research note on Monday, December 4th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. assumed coverage on shares of Apellis Pharmaceuticals in a research note on Monday, December 4th. They issued an “overweight” rating and a $31.00 price target for the company. Finally, Citigroup assumed coverage on shares of Apellis Pharmaceuticals in a research note on Monday, December 4th. They issued a “buy” rating and a $23.00 price target for the company.

Apellis Pharmaceuticals (APLS) traded up $0.98 during mid-day trading on Thursday, reaching $20.53. 51,326 shares of the company’s stock were exchanged, compared to its average volume of 171,609. Apellis Pharmaceuticals has a fifty-two week low of $12.45 and a fifty-two week high of $20.65. The stock has a market cap of $923.57 and a PE ratio of -25.66.

In other Apellis Pharmaceuticals news, major shareholder Global Strategic Fund I. Venbio acquired 127,515 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was bought at an average price of $14.00 per share, with a total value of $1,785,210.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

ILLEGAL ACTIVITY WARNING: “Apellis Pharmaceuticals (APLS) Getting Somewhat Positive News Coverage, Analysis Shows” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/apellis-pharmaceuticals-apls-getting-somewhat-positive-news-coverage-analysis-shows/1786693.html.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade.

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.